A study to compare two Siddha medicines (Avaraiyathi Chooranam and Madhumega Chooranam) for controlling blood sugar in participants with Type 2 Diabetes at National Institute of Siddha, Chennai

A Comparative Study on the effect of the Avaraiyathi Chooranam and Madhumega Chooranam in the management of Madhumegam (Diabetes Mellitus -Type II) An Open label, Randomized controlled trial in patients reporting at Ayothidoss Pandithar Hospital, National Institute of Siddha. - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/02/103076

Enrollment

200

Registered

2026-02-05

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Avaraiyathi Chooranam: Internal Medicine 5 gram Twice a day with Hot Water for 90 days Control Intervention1: Madhumega Chooranam : Internal Medicine 2 Capsules Twice a day with Hot wat

Eligibility

Inclusion criteria

Inclusion criteria: Glycosylated Hemoglobin (HbA1c) More than 6.5 percent and Less than 9 percent Newly diagnosed type II diabetes mellitus patients

Exclusion criteria

Exclusion criteria: Participants of Type-I DM (insulin dependent DM) or Type-II DM on insulin Participants with current diagnosis of malignancy Participants suffering from major systemic illness necessitating long term drug treatment (TB, AIDS) Pregnant and Lactating women Participants who have participation in any other clinical trial

Design outcomes

Primary

Measure	Time frame
Difference of objective parameter HbA1c, Serum fasting glucose and postprandial glucose in both arms (Minimal Clinical Importance Difference of HbA1c-0.5 Percent) Timepoint: 3 months	—

Secondary

Measure	Time frame
Difference of Fasting lipid sub fractions in both arms. Difference of HOMA IR test in sub groups (20 patients from each group- every 5th person) at base line and after 3 months. Timepoint: 3 months	—

Countries

India

Contacts

Public ContactHITHA SHYAM MS

National Institute of Siddha

dr.vetha@gmail.com9894782366

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026